MarketInOut Stock Screener Log In | Sign Up

Anavex Life Sciences Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Anavex Life Sciences Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization121.43 mln
Float91.12 mln
Earnings Date11/30/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

16 / 100
Significantly lagging

ROE

-11.91
Negative

ROA

-11.07
Deeply negative

Business Description

Anavex Life Sciences Corp. is a drug development company focused on finding new treatments for brain and nervous system conditions, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and certain cancers. Its most advanced compound, blarcamesine, is a pill designed to support healthy cell function and has been tested in multiple clinical trials across several of these conditions. The company is also advancing a second drug candidate that has shown promise in slowing the progression of Alzheimer's disease in laboratory studies. Founded in 2004, Anavex is headquartered in New York City.

Key Fundamentals

EPS-0.14
ROE-11.91
ROIC-916
ROA-11.07
EBITDA, mln-13.11
EV / EBITDA-5.30
EV / EBIT-5.30

Quote Details

Last 1.19
Change -0.11 (-8.46%)
Open 1.30
Volume 1,195,922
Turnover 1,423,147
Average Volume 1,326,434

Financial Ratios

Leverage Ratio1.07
Current Ratio15.62
Price / Book1.67
Price / Tangible Book1.67

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio16.63
Short % of Float14.89

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -10.53% 9 / 100   
1 Month -37.04% 8 / 100   
2 Months -52.4% 8 / 100   
6 Months -64.16% 8 / 100   
1 Year -85.16% 7 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog